Evaluation of the potential of tumor-targeted manganese-iron oxide magnetic nanoparticle hybrid imaging agent
Project no. 22568 · Status: Kapanmış · 2021
Summary
<p>Cancer is one of the most significant global health issues today. The treatment of cancer is considered one of the most expensive, challenging, and labor-intensive treatments worldwide. Traditional treatments such as chemotherapy, radiotherapy, and surgery have limitations and certain drawbacks. To achieve more effective treatment, there has been a growing focus on the design of nano-guided systems using theranostic agents that do not cause side effects in patients, target tumors, and have high therapy success rates. However, the most important factor in treatment success is the accurate staging of the disease and the proper evaluation of the response to treatment. For this reason, studies on hybrid or multimodal imaging methods to ensure proper imaging of organs and improve image quality have gained importance in recent years. Due to the sensitivity of positron emission tomography (PET) scanners and the spatial resolution of magnetic resonance imaging (MRI), PET/MR combinations are a hybrid imaging system that provides the best anatomical and functional information simultaneously.</p><p>The proposed thesis project aims to design and evaluate the potential of a tumor-targeted radiolabeled (⁶⁸Ga/¹²⁴I/⁸⁹Zr) nanoparticle and a PET/MR agent. To this end, a new dual-modality MR agent will be synthesized by conjugating T1 and T2 contrast materials, which are currently used as MR contrast agents, onto a nanoplatform. The tumor-targeting agent will be integrated into the nanoparticles, and the nanoparticles will be radiolabeled to determine their nuclear imaging potential. The structural characterization of the synthesized nanoparticles will be determined using XRD, FTIR, DLS, and Zeta sizer. SEM and TEM images will be obtained. The cytotoxic effects on cancer cells will be determined in vitro. At the same time, the in vitro dual-mode T1 and T2-weighted MR potential of the nanoplatform will be determined in cell lines.</p><p>The aim of this thesis is to contribute to the literature with a radiolabeled antibody-integrated magnetic nanoplatform intended for use in PET/MR hybrid imaging of breast cancer and to introduce a new agent that can be used in addition to existing agents used in the development of hybrid images.</p>